Immunological tests in urology: when they are prescribed

The term "immunological testing in urology" is partly historical and overly broad. In modern practice, it can encompass a wide range of things: serology for urogenital infections, antisperm antibody testing, cytology and urinary tumor markers for bladder cancer, and immunohistochemical and molecular markers for advanced urothelial cancer. There is no universal "urological immune profile" that would be suitable for all patients.

In routine urology, the basis for diagnosis often remains microbiological, morphological, and instrumental rather than immunological. In uncomplicated cystitis and recurrent urinary tract infections, symptoms, urinalysis, dipstick testing, urine culture, and risk factor assessment are crucial, rather than serological panels or "immunograms." The European Association of Urology and the American Urological Association emphasize urine culture and the clinical context. [2]

In andrology, the immunological focus has narrowed even further. Antisperm antibody tests haven't disappeared, but they've effectively disappeared from the routine initial evaluation of men with infertility. Current guidelines from the American Urological Association and the American Society for Reproductive Medicine explicitly discourage this test from being performed in the initial evaluation of male infertility. [3]

In uro-oncology, immunological and molecular markers, on the other hand, have become more important, but their role is also strictly limited. In the diagnosis of non-muscle-invasive bladder cancer, urine cytology and urinary markers are considered complementary to cystoscopy, not a replacement for it. In advanced urothelial cancer, immunohistochemistry of programmed death ligand 1 and molecular abnormalities of fibroblast growth factor 3 can change treatment, but not in all patients and not at all stages of the disease. [4]

The main modern principle is this: immunological testing in urology is needed not when one wants to "check immunity," but when the results will truly change tactics. If the analysis doesn't answer a specific question about diagnosis, prognosis, or treatment choice, it often creates noise rather than benefit. This is why new guidelines in urology have become significantly more selective. [5]

Table 1. What immunological and related studies are actually used in urology

Direction	Study	Role today
Urogenital infections	Serology for syphilis, type-specific serology for herpes simplex virus in certain situations	Highly specialized, not routine for everyone
Urethritis	Nucleic acid amplification tests for chlamydia, gonococcus and other pathogens	Much more important than conventional serology
Male infertility	Antisperm antibodies	Not routinely, only in certain scenarios
Non-muscle-invasive bladder cancer	Urine cytology and urinary tumor markers	Only as an adjunct to cystoscopy
Disseminated urothelial cancer	Immunohistochemistry of programmed death ligand 1, search for abnormalities of fibroblast growth factor 3	Predictive role in some patients
Research panels	Cytokines, immune signatures, circulating tumor deoxyribonucleic acid	Promising, but not routine

Sources for the table. [6]

Urologic and Sexually Transmitted Infections: Where Immunology Is Helpful and Where It Isn't

In the case of a common bacterial urinary tract infection, immunological tests are not the mainstay of diagnosis. The European Association of Urology recommends relying on symptoms and dipstick testing for acute cystitis, and performing a urine culture if pyelonephritis is suspected, if there are atypical symptoms, pregnancy, or if symptoms persist or recur rapidly. The American Urological Association, in its guidelines for recurrent urinary tract infection, also emphasizes that urine culture remains the primary diagnostic tool for an episode of cystitis. [7]

This leads to an important practical conclusion: for recurrent urinary tract infections, routine serological panels, antibodies to uropathogens, and extensive "immunograms" are not part of the standard regimen. Questions need to be asked differently: is each episode confirmed by culture, are there any anatomical or behavioral risk factors, is asymptomatic bacteriuria being treated unnecessarily, and is there any pregnancy or invasive urological interventions. This is precisely the logic that is considered evidence-based today. [8]

The situation is different with urethritis, but here too, classic serological tests do not play a leading role. The European Association of Urology recommends taking a swab from the urethra and performing a validated nucleic acid amplification test on the first portion of urine or a urethral swab before initiating empirical therapy if gonococcal or non-gonococcal urethritis is suspected. In other words, the modern standard has shifted toward direct detection of the pathogen rather than searching for an immune response to it. [9]

Serology remains useful in urological infectious disease practice, but only in limited settings. Guidelines from the US Centers for Disease Control and Prevention (CDC) indicate that syphilis serology is mandatory for genital ulcers, and that type-specific virological testing from the lesion and, if necessary, type-specific serology for the herpes simplex virus are used if genital herpes is suspected. Such serology is not recommended for asymptomatic screening of all men for herpes. [10]

Thus, in infectious urology, immunology is useful in specific areas: for syphilis, certain herpes cases, and some complex cases of sexually transmitted infections. But for most patients with cystitis, pyelonephritis, or urethritis, culture methods, nucleic acid amplification tests, and a competent clinical assessment are crucial. This is the main modern dividing line between useful immunology and unnecessary testing. [11]

Table 2. Infectious urology: what tests are really needed

Clinical situation	Preferred test	The role of immunological tests
Acute uncomplicated cystitis	General urine analysis, test strip, sometimes culture	Usually minor
Recurrent urinary tract infection	Urine culture with sensitivity	Serology is not routine
Urethritis	Nucleic acid amplification tests on the first urine sample or swab	More important than classical serology
Genital ulcer	Syphilis serology, herpes virological testing	High value
Suspected genital herpes without a lesion	Type-specific serology in individual cases	Electoral value
Pregnancy and suspected urinary tract infection	Urine culture is especially important	Immunological tests are secondary

Sources for the table. [12]

Male Infertility: Antisperm Antibodies and Why They've Faded from Routine Use

Antisperm antibodies remain the most classic example of an immunological test in andrology. Their concept is physiologically understandable: when the testicular immune barrier is compromised, the body can produce antibodies to its own sperm, potentially impairing their motility, interaction with cervical mucus, and fertilization ability. However, the current challenge lies not in the biological logic, but in the clinical applicability of the test. [13]

This is why modern recommendations have become much more cautious. The American Urological Association and the American Society for Reproductive Medicine explicitly recommend against testing for antisperm antibodies in the initial evaluation of male infertility. This is a significant shift from older approaches, where such testing was ordered much more widely. [14]

If the test is discussed, it's usually not a standard screening for all men, but rather in selected clinical situations. The World Health Organization, in its guidelines for semen analysis, considered sperm agglutination as a sign that could suggest the presence of antisperm antibodies, while modern reviews most often list severe agglutination, certain forms of asthenozoospermia, previous vasectomy, trauma, testicular torsion, and inflammatory diseases of the genital tract as potential indications. However, this is no longer a guideline-level routine, but a targeted use. [15]

In modern male infertility diagnostics, the European Association of Urologists (EAU) places primary emphasis not on immunology, but on more effective approaches: comprehensive semen analysis, genetic testing for severe oligozoospermia and azoospermia, the search for mutations in the cystic fibrosis transmembrane regulator (CFTR) in bilateral vas deferens, and the study of Y-chromosome microdeletions. This demonstrates that by 2026, immunology in andrology will no longer be central, but rather complementary. [16]

In practice, this means the following: antisperm antibodies haven't disappeared from andrology, but their role has become niche. If a couple is experiencing infertility, the first steps today are a medical history, physical examination, at least two semen analyses, and, if necessary, genetic and hormonal evaluation. Immunological testing is only included when there is a clear indication that it could truly change the treatment plan. [17]

Table 3. Antisperm antibodies: what has changed in modern practice

Question	A modern answer
Should all men with infertility take this test?	No
Is the test an initial stage of the examination?	No
When can it be discussed?	In cases of severe sperm agglutination and certain suspicious scenarios
What is more important at the start?	Repeat semen analysis, anamnesis, examination, hormones, genetics
Can the test itself explain infertility?	Usually no
Does it change tactics for all patients?	No, only for a limited group

Sources for the table. [18]

Urological oncology: urine cytology and urinary tumor markers

In modern uro-oncology, the most important "immunological and related" tests relate to bladder cancer. Here, urine cytology remains the classic test. The European Association of Urology emphasizes that cytology is particularly useful as a complement to cystoscopy for detecting high-grade tumors and carcinoma in situ, while it is significantly less sensitive for low-grade tumors. Current guidelines indicate a high sensitivity of approximately 84% for high-grade tumors and a low sensitivity of approximately 16% for low-grade tumors. [19]

Urinary molecular and protein markers are rapidly developing, and there are already many of them. The European Association of Urology guidelines list such approaches as UroVysion, nuclear matrix protein 22, fibroblast growth factor receptor 3 mutations, telomerase reverse transcriptase promoter mutations, and other panels. However, the guidelines' overall conclusion is very cautious: such tests typically gain sensitivity at the expense of specificity, and benign conditions and previous intravesical therapy with bacillus Calmette-Guérin can bias the results. [20]

The most important modern boundary is formulated very strictly: no existing urinary test replaces cystoscopy. The European Association of Urology explicitly states that no available test can replace cystoscopy in the evaluation of patients with suspected bladder cancer, and the American Urological Association, in its guidelines for non-muscle-invasive bladder cancer, specifically states that urinary biomarkers should not be used instead of cystoscopy for surveillance. [21]

This does not mean, however, that urinary markers are useless. In certain scenarios, they have a complementary role. The European Association of Urology permits the use of cytology as an adjunct to cystoscopy for high-grade tumors and also allows the use of a marker and/or ultrasound in the monitoring of selected patients with low-risk tumors if cystoscopy is not possible or the patient refuses it. The American Urological Association, in its guidelines on microhematuria, allows the use of urine cytology or validated urinary tumor markers to guide the decision to perform cystoscopy in some appropriately counseled patients. [22]

The practical conclusion is simple. Cytology and urinary markers are tools for clarification, not a standalone replacement for endoscopy. They are particularly useful when it comes to increasing the likelihood of detecting a high-grade process, supporting the decision to perform cystoscopy, or monitoring a limited group of patients outside the standard endoscopic scenario. However, viewing them as a quick "noninvasive test instead of cystoscopy" is incorrect. [23]

Table 4. Urinary markers in bladder cancer: the real role

Study	What does it do best?	The main limitation
Urine cytology	Detection of high-grade tumors and carcinoma in situ	Poor sensitivity for low-grade tumors
UroVysion	Helps as an additional molecular test	Does not replace cystoscopy
Nuclear matrix protein 22	Increases sensitivity in a number of scenarios	Specificity is lower, false positive results are possible
Mutations in urinary fibroblast growth factor receptor 3	A promising molecular marker	Not yet a universal routine standard
Telomerase reverse transcriptase promoter mutations	A promising additional marker	Does not replace endoscopy
Any urinary marker in general	Supplement to the clinic and cystoscopy	Not suitable as a single test

Sources for the table. [24]

Immunohistochemical and molecular markers in advanced urothelial carcinoma

While cystoscopy plays a key role in the diagnosis of non-muscle-invasive bladder cancer, in advanced urothelial cancer, some immunological and molecular markers already have a real impact on the choice of systemic therapy. However, there is an important limitation here: outside of clinical trials, not everything that looks promising has become routine practice. The European Association of Urology explicitly states that molecular classification, expression profiling, and even immunohistochemical subtypes are not yet part of standard routine workup outside of clinical trials. [25]

The most practical example of a useful molecular test today is the detection of sensitive abnormalities of fibroblast growth factor receptor 3. In the European Association of Urology guidelines, this is no longer a research detail, but a full-fledged strong recommendation: in unresectable or metastatic urothelial cancer, sensitive abnormalities of fibroblast growth factor receptor 3 are used to select patients for erdafitinib. This is a good example of how a molecular marker can truly change therapy. [26]

Programmed death ligand 1 immunohistochemistry also plays a role, but in a much more limited sense than is often thought. The European Association of Urology guidelines emphasize that the main drawback of programmed death ligand 1 staining is that a significant proportion of patients with a negative status still respond to immune checkpoint blockade. Therefore, the test is not a universal "marker of immune therapy benefit." Currently, its role is primarily associated with the selection of individual previously untreated patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin and for whom monotherapy with certain immunotherapy agents is being considered. [27]

Other promising areas have not yet achieved the status of routine, mandatory testing. The same European Association of Urology guidelines state that there is insufficient evidence for tumor mutational load, molecular variants, and immune-expression signatures to support their use in routine patient care. Circulating tumor deoxyribonucleic acid (CDNA) appears very promising as a prognostic and predictive marker, but it is still an area of active development and not a standard for every patient. [28]

Consequently, modern urologic oncology utilizes immunological and molecular research in a targeted manner. If a marker can change drug selection, as in the case of fibroblast growth factor receptor 3, it becomes clinically actionable. However, if a marker merely improves understanding of tumor biology or is statistically associated with outcome but does not change standard treatment, its role remains primarily scientific or expert. This is the main rule for selecting such studies in practice. [29]

Table 5. Which predictive markers for urothelial cancer actually change tactics?

Marker	Status in modern practice	What does it change?
Fibroblast growth factor receptor 3 disorders	Routinely significant in the relevant clinical situation	Allows patient selection for erdafitinib
Programmable death ligand 1	Narrow predictive role	Helps in certain scenarios of choosing monotherapy with an immunotherapy drug
Molecular subtypes	So far it's mostly at the research level	Biology is clearer, but routine use is limited
Tumor mutational load	Promising, but not sufficient for routine management	Not yet a universally mandatory test
Circulating tumor deoxyribonucleic acid	Very promising	Possible prognosis and selection for treatment in the future

Sources for the table. [30]

What kind of analysis is needed when and what errors are most common?

The first and most common mistake is prescribing "immunology" when the issue can already be resolved with more direct methods. In the case of a typical urinary tract infection or urethritis, there's no point in replacing urine culture and nucleic acid amplification tests with broad serological panels. In such cases, immunological tests either don't provide the required accuracy or simply don't change the treatment strategy. [31]

The second typical mistake is overestimating antisperm antibodies. Even if such a test is positive, it does not automatically explain all of a couple's infertility and does not replace standard screening of both men and women. This is why leading modern guidelines have removed this test from the initial kit altogether, leaving it only a selective role. [32]

The third mistake is to view urinary tumor markers as a noninvasive replacement for cystoscopy. This is a very attractive idea for patients, but it is not supported by guidelines. Both the European and American Urological Associations maintain cystoscopy as the mainstay of diagnosis and monitoring for bladder cancer, and consider urinary markers only as an adjunct in specific scenarios. [33]

The fourth mistake is thinking that every immune or molecular marker in urothelial cancer should be tested in every patient. In practice, the range of routinely actionable markers is still limited. If a test doesn't help select a drug, doesn't change the prognosis for a specific decision here and now, and isn't part of the standard care, its use must be very well justified. [34]

Therefore, the safest practical algorithm is to first formulate a clinical question, then select a test that can realistically answer it, and only then discuss more complex immunological or molecular studies. This approach simultaneously reduces test overruns, the number of false positives, and delays in effective treatment. [35]

Table 6. Practical algorithm: which test is needed in which situation

Clinical task	What is prescribed first?	What is not usually needed routinely
Cystitis or recurrent urinary tract infection	General urine analysis, test strip, urine culture as indicated	Serology to uropathogens, general immunogram
Urethritis	Smear and nucleic acid amplification tests	Broad serological panels without indications
Genital ulcer	Syphilis serology, herpes testing	Non-selective "all-in-one" panels
Male infertility at the start	Repeated sperm analysis, anamnesis, examination, hormones, genetics as indicated	Routine antisperm antibody test
Suspected bladder cancer	Cystoscopy, urine cytology as an adjunct	An attempt to replace cystoscopy with only a urine marker
Metastatic urothelial cancer	Markers that actually influence treatment choices, such as fibroblast growth factor receptor 3 in the right situation	All possible molecular panels without practical purpose

Sources for the table. [36]

FAQ

What is actually called immunological testing in urology today?
It's not a single specific test, but a group of tests: serology for certain urogenital infections, antisperm antibodies in specific andrology scenarios, urine cytology and urinary tumor markers for bladder cancer, as well as immunohistochemical and molecular markers for advanced urothelial cancer. [37]

Is it necessary to have an immunogram for recurrent urinary tract infections?
Routinely, no. Current urological guidelines base the diagnosis of recurrent urinary tract infections on urine culture, risk factor analysis, and appropriate management strategies, rather than on general immunological panels. [38]

What immunological test is truly important for genital ulcers?
Serology for syphilis is the most important. If herpes is suspected, type-specific testing from the lesion is used, and in certain situations, type-specific serology is used. [39]

Should all infertile men be tested for antisperm antibodies?
No. Current guidelines from the American Urological Association and the American Society for Reproductive Medicine advise against this test in the initial evaluation of male infertility. [40]

When is antisperm antibody testing considered?
Typically in specific situations, such as with severe sperm agglutination or a corresponding medical history, but it is no longer a routine test for all patients. [41]

Can urine cytology replace cystoscopy?
No. The European Association of Urology clearly states that none of the existing tests replace cystoscopy, and cytology is used as a supplement, primarily for high-grade tumors. [42]

Are urinary tumor markers needed in all patients with microhematuria?
No. Their place is limited. American guidelines allow the use of cytology or validated urinary markers in some appropriately counseled patients to guide the decision about cystoscopy, but this is not a universal standard for everyone. [43]

Which immunological and molecular tests for urothelial cancer actually change treatment?
The most practical example is the search for sensitive abnormalities of the fibroblast growth factor receptor 3, as it helps select patients for erdafitinib. [44]

Should all patients with urothelial cancer have programmed death ligand 1 testing?
No. Its role is limited to specific clinical situations. Furthermore, a negative status does not preclude a response to immune therapy, so it is not a universal marker of benefit. [45]

What remains research-based rather than routine today?
Molecular subtypes, immune-expression signatures, tumor mutational load, and some circulating tumor deoxyribonucleic acid panels are still considered promising, but not mandatory routine practice for every patient. [46]

The biggest mistake when prescribing immunological tests in urology?
Prescribing them without a clear clinical question. If the test doesn't change the diagnosis, prognosis, or treatment choice, it creates more confusion than it helps. [47]